← All candidates
Six insider buys in the last year — $128.7K in all.
16 filings on record.
PMCBPharmaCyte Biotech, Inc.
—
$0.4502
-2.47% · Sep 15
Six insider buys in the last year — $128.7K in all.
Nothing in the last fortnight.
Price · 1Y · daily● 6 buys
▸ hover a marker for the filing · drag to zoom · daily bars sharpen to 30-min on close ranges · 4 moves explained
Reverse-split 1×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what PMCB ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Short % float
Pro
The buyers
▸ each insider's past open-market buys, measured ~6 months (120 trading days) later, against the S&P over the same spans · split-adjusted · pre-scheduled 10b5-1 plan trades excluded · past outcomes, not predictions
CEO and President
Silverman Joshua
Bought $33.3K on Jan 7 — 40,000 sh @ $0.8329, held direct, 9.6% of their stake.
0 of 1 position beat the S&P
Director
Schechter Jonathan
Bought $16.9K on Jan 7 — 20,000 sh @ $0.8436, held direct, 10% of their stake.
0 of 2 positions beat the S&P
The record
newest first
DateTypeInsiderOf stakeShares @ priceValue
11 more transactions on Pro →Context
Earnings · EPS vs forecast
2 of 4 quarters beat
Q3 '22−$0.07 act+$0.00
Q2 '22−$0.06 act−$0.02
Q1 '22−$0.04 act+$0.01
Q4 '21−$0.06 act+$0.01
The file stays open
16 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice